Parkman Healthcare Partners LLC Invests $20.02 Million in Zimmer Biomet Holdings, Inc. $ZBH

Parkman Healthcare Partners LLC purchased a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 232,557 shares of the medical equipment provider’s stock, valued at approximately $20,021,000. Zimmer Biomet accounts for about 2.0% of Parkman Healthcare Partners LLC’s holdings, making the stock its 16th largest holding. Parkman Healthcare Partners LLC owned 0.12% of Zimmer Biomet as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Dodge & Cox increased its position in shares of Zimmer Biomet by 1.3% during the fourth quarter. Dodge & Cox now owns 23,506,849 shares of the medical equipment provider’s stock worth $2,113,736,000 after acquiring an additional 290,676 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Zimmer Biomet by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 23,483,741 shares of the medical equipment provider’s stock valued at $2,111,658,000 after purchasing an additional 192,517 shares during the period. BlackRock Inc. bought a new position in Zimmer Biomet in the second quarter worth approximately $1,344,282,000. State Street Corp increased its holdings in Zimmer Biomet by 2.3% during the 4th quarter. State Street Corp now owns 8,826,974 shares of the medical equipment provider’s stock worth $795,814,000 after purchasing an additional 195,214 shares during the period. Finally, Franklin Resources Inc. increased its holdings in Zimmer Biomet by 43.2% during the 4th quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider’s stock worth $601,204,000 after purchasing an additional 2,017,857 shares during the period. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Shares of ZBH opened at $100.89 on Tuesday. The company has a 50 day moving average of $92.90 and a two-hundred day moving average of $91.14. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50. Zimmer Biomet Holdings, Inc. has a twelve month low of $79.12 and a twelve month high of $108.29. The company has a market cap of $19.24 billion, a price-to-earnings ratio of 24.55, a price-to-earnings-growth ratio of 2.75 and a beta of 0.45.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, beating the consensus estimate of $2.01 by $0.06. The firm had revenue of $2.18 billion during the quarter, compared to analyst estimates of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The business’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, analysts predict that Zimmer Biomet Holdings, Inc. will post 8.54 earnings per share for the current fiscal year.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the transaction, the insider directly owned 27,251 shares of the company’s stock, valued at approximately $2,252,022.64. This trade represents a 15.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 1.28% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Barclays lowered their target price on Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating for the company in a report on Wednesday, April 29th. Truist Financial raised their price target on Zimmer Biomet from $92.00 to $106.00 and gave the company a “hold” rating in a research note on Thursday, August 6th. Wells Fargo & Company lowered their price objective on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 29th. Stifel Nicolaus increased their target price on shares of Zimmer Biomet from $105.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Finally, Zacks Research downgraded shares of Zimmer Biomet from a “hold” rating to a “strong sell” rating in a research report on Monday, July 27th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $104.42.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.